article · AIDS Research and Therapy
BACKGROUND: Viral load is the most reliable indicator of antiretroviral therapy response and treatment failure. In Ethiopia, virologic failure remains a major challenge despite expanded ART coverage. OBJECTIVE: To identify determinants of virologic failure among adults on first-line antiretroviral therapy in health facilities of Awi Zone, Northwest Ethiopia. METHODS: An institution-based unmatched case-control study with a 1:2 ratio was conducted among 369 participants (123 cases and 246 controls). Cases were HIV-infected clients aged ≥ 15 years with virologic failure (viral load > 1000 copies/mL on two consecutive tests after adherence support) between 30 October 2020 and 30 December 2024. Controls were HIV-infected clients aged ≥ 15 years on first-line ART with viral load ≤ 1000 copies/mL on two consecutive tests after ≥ 6 months of treatment during the study period. Participants were selected using computer-generated simple random sampling from selected facilities. Bivariable and multivariable binary logistic regression analyses were performed to identify independent determinants of virologic failure. RESULTS: Multivariable analysis identified non-disclosure of HIV status (AOR = 2.24, 95% CI: 1.11-5.22), viral load after ART initiation > 1000 copies/mL (AOR = 5.32, 95% CI: 3.32-7.15), poor treatment adherence (AOR = 5.64, 95% CI: 2.01-7.32), treatment interruption (AOR = 6.45, 95% CI: 3.95-14.01), being single (AOR = 2.34, 95% CI: 1.54-5.32), and CD4 count < 200 cells/mm³ (AOR = 4.90, 95% CI: 2.40-8.25) as significant determinants of virologic failure. CONCLUSION: Strengthening adherence support, retention in care, and disclosure counseling is essential to reduce virologic failure.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1186/s12981-026-00904-2
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.